endogene.bio has been selected for the inaugural virtual Eli Lilly and Company Gateway Labs program, a 12-month accelerator that kicked off in London last week.
Through the program, we'll benefit from Lilly's Gateway model, connecting early-stage companies with scientific and development expertise at Lilly, alongside a network of leading advisors and investment partners.
We are proud to be part of this cohort focused on improving women's lives by transforming treatment for conditions that affect hundreds of millions of women worldwide.
This milestone reflects the growing momentum behind women's health and the increasing recognition of the need for better therapies in conditions such as endometriosis.
We look forward to working alongside Lilly as we continue building the future of uterine health.
About endogene.bio
endogene.bio generates high-resolution biological data from menstrual blood, unlocking a previously inaccessible layer of human uterine biology. Our platform enables disease understanding, patient stratification, and therapeutic discovery across uterine health.
